CLN7 disease

CLN7 disease, also known as variant late-infantile neuronal ceroid lipofuscinosis type 7 (vLINCL), is a rare inherited neurodegenerative disorder belonging to the neuronal ceroid lipofuscinoses (NCLs), a group of lysosomal storage diseases collectively referred to as Batten disease. It is caused by mutations in the MFSD8 gene (also called CLN7), which encodes a lysosomal membrane protein involved in transporting molecules across the lysosomal membrane. Loss of function of this protein leads to the accumulation of ceroid lipofuscin, an autofluorescent lipopigment, within neurons and other cells, resulting in progressive neurodegeneration. CLN7 disease primarily affects the central nervous system. Onset typically occurs between ages 2 and 7 years, often beginning with seizures (epilepsy), progressive loss of vision leading to blindness, cognitive and motor regression, speech deterioration, and movement abnormalities including ataxia and myoclonus. Children who were previously developing normally begin to lose acquired skills. As the disease progresses, affected individuals develop severe intellectual disability, loss of motor function, and eventually become bedridden. Retinal degeneration is a hallmark feature, and brain MRI typically shows progressive cerebral and cerebellar atrophy. There is currently no cure for CLN7 disease. Treatment is supportive and symptomatic, focusing on seizure management with antiepileptic medications, physical and occupational therapy to maintain function as long as possible, nutritional support, and palliative care. Gene therapy approaches and other experimental treatments are under investigation in preclinical and early clinical research. The disease follows a progressive course, and life expectancy is significantly reduced, with most affected individuals surviving into their teens or early adulthood.

Common questions about CLN7 disease